PMID- 18067997
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20071210
IS  - 0188-4409 (Print)
IS  - 0188-4409 (Linking)
VI  - 39
IP  - 1
DP  - 2008 Jan
TI  - Improved immune function with donor B-cell infusion after semi-allogeneic bone 
      marrow transplantation in mice.
PG  - 61-8
AB  - BACKGROUND: Regeneration of the immune system after bone marrow transplantation 
      (BMT) is a slow process, often prolonged by the development and treatment of 
      graft vs. host disease (GVHD). Donor lymphocyte infusion using allogeneic T-cells 
      is widely applied for the induction of GVHD, which is associated with the desired 
      graft vs. leukemia effect. Due to the slow immune recovery, our objective was to 
      accelerate the immune recovery post-BMT by B-cell injections. METHODS: 
      T-cell-depleted stem cells obtained from female C57BL/6 (B6) mice were 
      transplanted into lethally irradiated (Balb/c x C57BL/6) F-1 female mice. Seven 
      days post-transplantation, murine B-cells of male C57BL/6 origin were infused 
      into the T-cell-depleted chimeras. Thirty and 60 days post-transplantation, PCR 
      analysis of the Y-chromosome was carried out to detect male B-cells in the 
      transplant recipients. In order to evaluate the specific antibody response, the 
      donors were immunized by specific T-cell-dependent and -independent antigens. 
      RESULTS: None of the T-cell-depleted transplanted mice developed GVHD during a 
      follow-up period of 650 days, whereas all non-T-cell-depleted recipients died. At 
      60 days post-transplantation, significantly higher levels of immunoglobulins 
      (IgA, IgG1, IgG3 isotypes) were seen in chimeras supplemented with male B-cells 
      than in chimeras reconstituted with T-cell-depleted stem cells alone. 
      CONCLUSIONS: Our data document the feasibility of administering B-cell therapy 
      post-allogeneic BMT to improve recovery of the humeral arm of the immune system 
      while avoiding GVHD. Furthermore, post-transplant B-cell administration may have 
      an important impact as an alternative to IV immunoglobulin infusions.
FAU - Samuel, Simcha
AU  - Samuel S
AD  - Department of Bone Marrow Transplantation, Hadassah-Hebrew University Medical 
      Center, Jerusalem, Israel.
FAU - Azar, Yehudith
AU  - Azar Y
FAU - Corchia, Nataly
AU  - Corchia N
FAU - Or, Reuven
AU  - Or R
LA  - eng
PT  - Journal Article
DEP - 20070924
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/*transplantation
MH  - Bone Marrow Transplantation/immunology/*methods
MH  - Chimerism
MH  - Female
MH  - Graft vs Host Disease/immunology/*prevention & control
MH  - Immune System/*physiology
MH  - Immunoglobulins/blood
MH  - Lymphocyte Depletion
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - *Regeneration
MH  - T-Lymphocytes/immunology
MH  - Transplantation, Homologous/immunology/methods
EDAT- 2007/12/11 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/12/11 09:00
PHST- 2007/04/01 00:00 [received]
PHST- 2007/06/25 00:00 [accepted]
PHST- 2007/12/11 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/12/11 09:00 [entrez]
AID - S0188-4409(07)00240-8 [pii]
AID - 10.1016/j.arcmed.2007.06.018 [doi]
PST - ppublish
SO  - Arch Med Res. 2008 Jan;39(1):61-8. doi: 10.1016/j.arcmed.2007.06.018. Epub 2007 
      Sep 24.